Seqens Seqens

X

Find Radio Compass News for DSSTox_CID_28904

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

0

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

JP

0

Other Listed Suppliers

SERVICES

0

https://www.fiercepharma.com/pharma/argenx-snags-first-fda-approval-efgartigimod-win-generalized-myesthenia-gravis

F. Kansteiner FIERCEPHARMA
18 Dec 2021

https://www.globenewswire.com/news-release/2021/07/01/2256326/0/en/Oyster-Point-Pharma-Announces-Preclinical-Data-Highlighting-Potent-Activity-of-OC-01-varenicline-and-OC-02-simpinicline-Against-SARS-CoV-2-Virus-and-Variants.html

GLOBENEWSWIRE
01 Jul 2021

http://www.pharmafile.com/news/537616/china-approves-first-homegrown-hpv-vaccine

PHARMA FILE
08 Jan 2020

http://www.pharmafile.com/news/537616/china-approves-first-homegrown-hpv-vaccine

PHARMA FILE
07 Jan 2020

http://www.pharmafile.com/news/537616/china-approves-first-homegrown-hpv-vaccine

PHARMA FILE
07 Jan 2020

https://www.businesswire.com/news/home/20180627005347/en/Oyster-Point-Pharma-Announces-FDA-Clearance-Investigational

BUSINESSWIRE
27 Jun 2018

https://www.pharmacompass.com/pdf/news/list-of-off-patent-off-exclusivity-drugs-without-an-approved-generic-1499253832.pdf

FDA
04 Jul 2017
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY